Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IS EXPECTED TO REACH USD 7.67 BILLION BY 2028 FROM USD 3.35 BILLION IN 2022, GROWING AT A CAGR OF 14.81% DURING THE FORECAST PERIOD.
The Oncology Molecular Diagnostics Market Size, Share, & Trends Analysis Report By
- Product Type: Kits & Reagents and Instruments & Platforms
- Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, and Other
- Technology: Polymerase Chain Reaction (PCR), Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Sequencing, and Other
- End-user: Diagnostic Laboratories, Hospitals, and Other
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
ONCOLOGY MOLECULAR DIAGNOSTICS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2028) | USD 7.67 Billion |
| Market Size (2022) | USD 3.35 Billion |
| CAGR (2022-2028) | 14.81% |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| SEGMENTS BY | Product Type, Cancer Type, Technology, End-user, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY PLAYERS | Abbott, Agilent Technologies, Danaher, F. Hoffmann La-Roche, QIAGEN, and Siemens Healthineers |
MARKET INSIGHTS
The global oncology molecular diagnostics market size was valued at USD 3.35 billion in 2022 and is expected to reach USD 7.67 billion by 2028, growing at a CAGR of 14.81% during the forecast period. The field of oncology molecular diagnostics has witnessed remarkable advancements over the past few decades, transforming the landscape of cancer diagnosis and treatment. Molecular diagnostics in oncology involves the identification of genetic, molecular, and cellular alterations in cancer cells, enabling precise diagnosis, treatment selection, and monitoring of cancer patients.
Cancer is a complex and heterogeneous group of diseases characterized by uncontrolled cell growth and proliferation. Precise and early diagnosis, as well as personalized treatment approaches, are crucial for improving patient outcomes and reducing the burden of cancer. The oncology molecular diagnostics market has emerged as a critical tool in achieving these objectives. Moreover, molecular diagnostics enable the customization of cancer treatment plans based on an individual's tumor's genetic and molecular characteristics. This approach, known as precision medicine, maximizes treatment efficacy while minimizing adverse effects. Molecular tests can detect cancer at its earliest stages, often before clinical symptoms manifest. Early diagnosis increases the chances of successful treatment and improved survival rates.
While the oncology molecular diagnostics market holds immense promise, it faces challenges, including regulatory complexities, cost barriers, and skilled workforce concerns. However, the future is positive, with ongoing technological advancements, increasing accessibility, and a growing focus on early detection and personalized medicine. As research and development continue to flourish, molecular diagnostics will remain a cornerstone of oncology, shaping the future of cancer diagnosis and treatment. Overall, the oncology molecular diagnostics market has emerged as a pivotal player in the fight against cancer. It provides precise insights into the genetic and molecular underpinnings of the disease, enabling personalized treatments and early detection. As technology evolves and healthcare systems embrace these innovations, molecular diagnostics will continue to drive advancements in cancer care, ultimately improving patient outcomes and reducing the global burden of cancer.
MARKET TRENDS & DRIVERS
Growing Significance of Companion Diagnostics for Oncology Drug Development
Companion diagnostics have become paramount in oncology drug development, aligning treatment decisions with patient-specific molecular profiles. These tests enable identifying individuals likely to respond to targeted therapies while excluding non-responders, enhancing treatment efficacy. As pharmaceutical companies increasingly integrate companion diagnostics into their drug development pipelines, precision medicine becomes a cornerstone of oncology, offering more effective and personalized treatment options for cancer patients. This growing significance of companion diagnostics is revolutionizing how oncology drugs are developed and administered, ultimately improving patient outcomes.
Increasing Partnerships & Collaboration for Development Of Oncology Molecular Diagnostics
Increasingly, partnerships and collaborations are shaping the landscape of oncology molecular diagnostics. Diagnostic companies, pharmaceutical firms, and research institutions are joining forces to develop cutting-edge molecular tests and companion diagnostics. These collaborations aim to accelerate the translation of genomic discoveries into clinical applications, enhancing the precision of cancer diagnosis and treatment and ultimately improving patient outcomes in the rapidly evolving field of oncology molecular diagnostics.
Emerging Immuno-oncology Based Cancer Treatments
Emerging immuno-oncology-based cancer treatments represent a prominent global oncology molecular diagnostics market trend. These therapies harness the body's immune system to combat cancer cells, emphasizing precision medicine. Molecular diagnostics play a pivotal role in identifying biomarkers for patient selection, monitoring treatment response, and developing innovative immuno-oncology therapies. This trend promises to revolutionize cancer care, offering more effective and personalized treatment options.
Rising Global Cancer Prevalence
The rising global cancer prevalence is a significant driver of the market. As cancer cases increase worldwide due to factors such as aging populations and lifestyle changes, there is a growing need for accurate and early cancer detection. Oncology molecular diagnostics play a crucial role in diagnosing and monitoring cancer, guiding treatment decisions, and ultimately improving patient outcomes in the face of this escalating global health challenge.
Transformation of Precision Cancer Care
The transformation of precision cancer care, driven by advances in molecular diagnostics, is a major catalyst for the growth of the oncology molecular diagnostics market. With a focus on tailoring treatments to individual genetic profiles, this paradigm shift enhances treatment efficacy, reduces side effects, and drives the demand for advanced diagnostic technologies in oncology. As oncologists increasingly rely on molecular insights to make informed treatment decisions, the market continues to expand to meet the growing need for personalized cancer care.
New Product Launches
New product launches are pivotal in driving the oncology molecular diagnostics market. These innovations continually expand the repertoire of diagnostic tools and solutions, enhancing molecular tests' accuracy, sensitivity, and clinical utility. By introducing novel assays, platforms, and technologies, new product launches empower healthcare providers to make more informed treatment decisions and improve patient outcomes in the ever-evolving field of oncology molecular diagnostics.
Technological Advancements in Molecular Diagnostics
Technological advancements in molecular diagnostics, including NGS, PCR techniques, and high-throughput platforms, are driving the oncology molecular diagnostics market. These innovations enable more accurate and comprehensive profiling of genetic and molecular alterations in cancer, facilitating personalized treatment strategies and early detection, ultimately improving patient outcomes and fueling market growth.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT TYPE
The global oncology molecular diagnostics market by product type is segmented into kits & reagents and instruments & platforms. The kits & reagents accounted for the market share in the product type segment in 2022 and is expected to grow at the highest CAGR during the forecast period. The kits & reagents are essential components of molecular diagnostics. They include DNA/RNA extraction kits, PCR reagents, nucleotide probes, and sequencing reagents. These products are vital for preparing and analyzing biological samples for cancer-specific biomarkers. Further, the instruments & platform category comprises various laboratory equipment and analytical instruments for molecular diagnostics, including PCR machines, NGS platforms, microarray scanners, and automated liquid handling systems. These instruments enable the processing and analysis of genetic and molecular data. Molecular diagnostic software is crucial in data analysis, interpretation, and reporting. It includes bioinformatics tools, data management software, and specialized algorithms for genomic analysis.
INSIGHTS BY CANCER TYPE
The global oncology molecular diagnostics market by cancer type is segmented into breast, colorectal, lung, blood, and other cancer types. In 2022, breast cancer dominated the global market share. Molecular diagnostics are crucial in breast cancer prognosis and treatment selection, identifying hormone receptor status (ER, PR) and HER2/neu amplification. Further, the colorectal cancer segment is expected to witness the highest segmental CAGR of over 15% during the forecast period. Colorectal cancer is a significant global health concern, accounting for millions of cancer-related deaths annually. Early detection and precise treatment are critical factors in improving patient outcomes.
INSIGHTS BY TECHNOLOGY
The polymerase chain reaction (PCR) technology segment held the most prominent share of the global oncology molecular diagnostics market 2022. PCR is a widely used technology that amplifies specific DNA sequences, allowing for the detection of genetic mutations and variations associated with various cancer types. It is known for its high sensitivity and specificity in identifying genetic abnormalities. Further sequencing segment is expected to grow at the highest CAGR in the technology during the forecast period. The field of oncology has witnessed a transformative shift in how cancer is diagnosed, characterized, and treated, largely owing to advancements in molecular diagnostics. Sequencing technology has emerged as a powerful tool among the various techniques driving progress in this domain.
INSIGHTS BY END-USER
The diagnostic laboratory end-user holds a dominant share of the global oncology molecular diagnostics market and is expected to witness the highest segmental CAGR during the forecast period. Diagnostic facilities perform molecular tests, including DNA and RNA analysis, to detect genetic mutations, biomarkers, and other cancer-related molecular alterations. Furthermore, hospital settings are significant consumers of molecular diagnostics in oncology. Oncology molecular diagnostics, encompassing various technologies such as DNA sequencing, PCR, and microarrays, have transformed cancer diagnosis, prognosis, and treatment decision-making. Hospitals are often the primary sites for diagnosing cancer. Oncology molecular diagnostics provide hospitals with precise tools to identify the presence of cancer, classify its type, and determine its molecular characteristics.
GEOGRAPHICAL ANALYSIS
North America accounted for the highest global oncology molecular diagnostics market share in 2022, accounting for over 46%. The region boasts a robust healthcare infrastructure, including specialized cancer centers and research institutions. This supports the development, validation, and adoption of molecular diagnostics. The region is at the forefront of technology and innovation, driving the rapid development of molecular diagnostic assays and platforms during the forecast. A significant number of clinical trials in oncology are conducted in North America, fostering the integration of molecular diagnostics into treatment decision-making. Well-defined regulatory processes, such as FDA approvals in the U.S., provide a clear pathway for market entry, boosting investor confidence.
Europe has witnessed a growing emphasis on personalized medicine, driving the adoption of oncology molecular diagnostics. Europe encourages collaborative research efforts, facilitating the development and validation novel diagnostic technologies. Regulatory agencies like the European Medicines Agency (EMA) have embraced companion diagnostics, increasing the use of molecular tests alongside targeted therapies. Universal healthcare systems in many European countries ensure broader access to molecular diagnostic tests, enhancing patient care. Further, the APAC is a rapidly growing oncology molecular diagnostics market due to its large population, increasing cancer prevalence, and investments in healthcare infrastructure.
COMPETITIVE LANDSCAPE
The global oncology molecular diagnostics market is fiercely competitive, driven by an ever-increasing demand for accurate cancer diagnosis and personalized treatment. The key players in the market, such as Abbott, Agilent Technologies, Danaher, F. Hoffmann-La Roche, QIAGEN, and Siemens Healthineers, among other prominent vendors, are driving the growth of oncology molecular diagnostics. Several key strategies shape competition in the global oncology molecular diagnostics market. For instance, companies invest heavily in research and development to create more accurate and cost-effective diagnostic assays and technologies. This includes advancements in NGS, liquid biopsies, and companion diagnostics.
The global oncology molecular diagnostics market is characterized by intense competition, with established leaders and innovative newcomers striving to provide cutting-edge cancer diagnosis and treatment solutions. The market's future is poised for continued growth and evolution as technological advancements, increased understanding of cancer biology, and evolving healthcare needs shape the competitive landscape.
Frequently Asked Questions
How big is the oncology molecular diagnostics market?
What is the growth rate of the global oncology molecular diagnostics market?
Which region dominates the global oncology molecular diagnostics market share?
What are the significant trends in the oncology molecular diagnostics market?
Who are the key players in the global oncology molecular diagnostics market?
The global oncology molecular diagnostics market size is expected to grow at a CAGR of approximately 14.81% from 2022 to 2028.
The following factors are likely to contribute to the growth of the global oncology molecular diagnostics market during the forecast period:
- Rising Global Cancer Prevalence
- Transformation of Precision Cancer Care
- New Product Launches
- Technological Advancements in Molecular Diagnostics
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the global oncology molecular diagnostics market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Company Profiles
- Abbott
- Business Overview
- Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- Agilent Technologies
- Danaher
- F.Hoffmann La-Roche
- QIAGEN
- Siemens Healthineers
Other Prominent Vendors
- BD
- Business Overview
- Product Offerings
- BillionToOne
- Biocartis
- Biodesix
- bioMérieux
- Bio-Rad Laboratories
- Caris Life Sciences
- Epigenomics
- Exact Sciences
- Guardant Health
- Hologic
- Illumina
- Laboratory Corporation of America
- Lepu Medical Technology (Beijing)
- Myriad Genetics
- Sysmex Corporation
- Thermo Fisher Scientific
Segmentation by Product Type
- Kits & Reagents
- Instruments & Platforms
Segmentation by Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer
- Others
Segmentation by Technology
- Polymerase Chain Reaction (PCR)
- Hybridization
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Sequencing
- Other
Segmentation by End-user
- Diagnostic Laboratories
- Hospitals
- Other
Segmentation by Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
EXHIBIT 1 SEGMENTATION OF GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH (2022)
EXHIBIT 3 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 6 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 7 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 8 IMPACT OF GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS FOR ONCOLOGY DRUG DEVELOPMENT
EXHIBIT 9 IMPACT OF INCREASING PARTNERSHIPS & COLLABORATION FOR DEVELOPMENT OF ONCOLOGY MOLECULAR DIAGNOSTICS
EXHIBIT 10 IMPACT OF EMERGING IMMUNO-ONCOLOGY-BASED CANCER TREATMENTS
EXHIBIT 11 IMPACT OF RISING GLOBAL CANCER PREVALENCE
EXHIBIT 12 GLOBAL INCIDENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 13 INCIDENCE OF NEW CANCER CASES BY REGION (2020)
EXHIBIT 14 IMPACT OF TRANSFORMATION OF PRECISION CANCER CARE
EXHIBIT 15 IMPACT OF NEW PRODUCT LAUNCHES
EXHIBIT 16 IMPACT OF TECHNOLOGICAL ADVANCES IN MOLECULAR DIAGNOSTICS
EXHIBIT 17 IMPACT OF HIGH COST OF MOLECULAR DIAGNOSTICS TESTS
EXHIBIT 18 IMPACT OF LACK OF SKILLED WORKFORCE & OPERATIONAL BARRIERS
EXHIBIT 19 IMPACT OF AVAILABILITY OF ALTERNATIVE TECHNOLOGIES IN CANCER DIAGNOSIS
EXHIBIT 20 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 21 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 22 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 23 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 24 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 25 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 26 FIVE FORCES ANALYSIS (2022)
EXHIBIT 27 INCREMENTAL GROWTH BY PRODUCT TYPE (2022 & 2028)
EXHIBIT 28 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 29 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 30 GLOBAL KITS & REAGENTS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 31 GLOBAL KITS & REAGENTS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 32 GLOBAL INSTRUMENTS & PLATFORM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 33 GLOBAL INSTRUMENTS & PLATFORM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 34 INCREMENTAL GROWTH BY CANCER TYPE (2022 & 2028)
EXHIBIT 35 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 36 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 37 GLOBAL BREAST CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 38 GLOBAL BREAST CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 39 GLOBAL COLORECTAL CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 40 GLOBAL COLORECTAL CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 41 GLOBAL LUNG CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL LUNG CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 43 GLOBAL BLOOD CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL BLOOD CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 45 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 47 INCREMENTAL GROWTH BY TECHNOLOGY (2022 & 2028)
EXHIBIT 48 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 49 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 50 GLOBAL PCR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 GLOBAL PCR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 52 GLOBAL HYBRIDIZATION ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 53 GLOBAL HYBRIDIZATION ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 54 GLOBAL INAAT ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL INAAT ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 56 GLOBAL SEQUENCING ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL SEQUENCING ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 58 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY END-USER (2022 & 2028)
EXHIBIT 61 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 62 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 63 GLOBAL DIAGNOSTIC LABORATORIES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL DIAGNOSTIC LABORATORIES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 65 GLOBAL HOSPITALS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL HOSPITALS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 67 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 68 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 69 INCREMENTAL GROWTH BY GEOGRAPHY (2022 & 2028)
EXHIBIT 70 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 71 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 72 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET: KEY COUNTRIES BY REVENUE 2022 ($ MILLION)
EXHIBIT 73 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 74 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN NORTH AMERICA 2022–2028 ($ MILLION)
EXHIBIT 75 INCREMENTAL GROWTH IN NORTH AMERICA (2022 & 2028)
EXHIBIT 76 US PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 77 US ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 78 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN CANADA 2022–2028 ($ MILLION)
EXHIBIT 79 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET: KEY COUNTRIES BY REVENUE 2022 ($ MILLION)
EXHIBIT 80 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN EUROPE 2022–2028 ($ MILLION)
EXHIBIT 82 INCREMENTAL GROWTH IN EUROPE (2022 & 2028)
EXHIBIT 83 PREVALENCE OF CANCER IN GERMANY (NUMBER OF NEW CASES) (2020)
EXHIBIT 84 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN GERMANY 2022–2028 ($ MILLION)
EXHIBIT 85 PREVALENCE OF CANCER IN FRANCE (NUMBER OF NEW CASES) (2020)
EXHIBIT 86 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN FRANCE 2022–2028 ($ MILLION)
EXHIBIT 87 UK PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 88 UK ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 89 PREVALENCE OF CANCER IN ITALY (NUMBER OF NEW CASES) (2020)
EXHIBIT 90 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN ITALY 2022–2028 ($ MILLION)
EXHIBIT 91 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN SPAIN 2022–2028 ($ MILLION)
EXHIBIT 92 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET: KEY COUNTRIES BY REVENUE 2022 ($ MILLION)
EXHIBIT 93 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 94 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028 ($ MILLION)
EXHIBIT 95 INCREMENTAL GROWTH IN APAC (2022 & 2028)
EXHIBIT 96 PREVALENCE OF CANCER IN CHINA (NUMBER OF NEW CASES) (2020)
EXHIBIT 97 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN CHINA 2022–2028 ($ MILLION)
EXHIBIT 98 PREVALENCE OF CANCER IN JAPAN (NUMBER OF NEW CASES) (2020)
EXHIBIT 99 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN JAPAN 2022–2028 ($ MILLION)
EXHIBIT 100 PREVALENCE OF CANCER IN INDIA (NUMBER OF NEW CASES) (2020)
EXHIBIT 101 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN INDIA 2022–2028 ($ MILLION)
EXHIBIT 102 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN SOUTH KOREA 2022–2028 ($ MILLION)
EXHIBIT 103 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN AUSTRALIA 2022–2028 ($ MILLION)
EXHIBIT 104 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET: KEY COUNTRIES BY REVENUE 2022 ($ MILLION)
EXHIBIT 105 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 106 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN LATIN AMERICA 2022–2028 ($ MILLION)
EXHIBIT 107 INCREMENTAL GROWTH IN LATIN AMERICA (2022 & 2028)
EXHIBIT 108 PREVALENCE OF CANCER IN BRAZIL (NUMBER OF NEW CASES) (2020)
EXHIBIT 109 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN BRAZIL 2022–2028 ($ MILLION)
EXHIBIT 110 PREVALENCE OF CANCER IN MEXICO (NUMBER OF NEW CASES) (2020)
EXHIBIT 111 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN MEXICO 2022–2028 ($ MILLION)
EXHIBIT 112 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN ARGENTINA 2022–2028 ($ MILLION)
EXHIBIT 113 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET: KEY COUNTRIES BY REVENUE 2022 ($ MILLION)
EXHIBIT 114 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 115 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN MIDDLE EAST & AFRICA 2022–2028 ($ MILLION)
EXHIBIT 116 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA (2022 & 2028)
EXHIBIT 117 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN TURKEY 2022–2028 ($ MILLION)
EXHIBIT 118 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN SAUDI ARABIA 2022–2028 ($ MILLION)
EXHIBIT 119 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET IN SOUTH AFRICA 2022–2028 ($ MILLION)
EXHIBIT 120 VENDORS OFFERING ONCOLOGY MOLECULAR DIAGNOSTICS PRODUCTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 121 VENDORS OFFERING COMMERCIAL ONCOLOGY MOLECULAR DIAGNOSTICS PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 122 ABBOTT: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 123 ABBOTT: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 124 ABBOTT: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 125 ABBOTT: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 126 AGILENT TECHNOLOGIES: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 127 AGILENT TECHNOLOGIES: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 128 AGILENT TECHNOLOGIES: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 129 AGILENT TECHNOLOGIES: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 130 DANAHER: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 131 DANAHER: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 132 DANAHER: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 133 DANAHER: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 134 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 135 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 136 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 137 QIAGEN: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 138 QIAGEN: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 139 QIAGEN: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 140 QIAGEN: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 141 SIEMENS HEALTHINEERS: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 142 SIEMENS HEALTHINEERS: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 143 SIEMENS HEALTHINEERS: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION (2016−2022)
TABLE 3 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET SIZE 2022–2028 ($ MILLION)
TABLE 4 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE: MARKET SIZE 2022–2028 ($ MILLION)
TABLE 5 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE: MARKET SIZE 2022–2028 ($ MILLION)
TABLE 6 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET SIZE 2022–2028 ($ MILLION)
TABLE 7 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER: MARKET SIZE 2022–2028 ($ MILLION)
TABLE 8 GLOBAL KITS & REAGENTS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 9 GLOBAL KITS & REAGENTS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 10 GLOBAL INSTRUMENTS & PLATFORM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 11 GLOBAL INSTRUMENTS & PLATFORM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 12 GLOBAL BREAST CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 13 GLOBAL BREAST CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 14 GLOBAL COLORECTAL CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 15 GLOBAL COLORECTAL CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 16 GLOBAL LUNG CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 17 GLOBAL LUNG CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 18 GLOBAL BLOOD CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 19 GLOBAL BLOOD CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 20 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 21 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 22 GLOBAL PCR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 23 GLOBAL PCR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 24 GLOBAL HYBRIDIZATION ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 25 GLOBAL HYBRIDIZATION ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 26 GLOBAL INAAT ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 27 GLOBAL INAAT ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 28 GLOBAL SEQUENCING ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 29 GLOBAL SEQUENCING ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 30 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 31 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 32 GLOBAL DIAGNOSTIC LABORATORIES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 33 GLOBAL DIAGNOSTIC LABORATORIES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 34 GLOBAL HOSPITALS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 35 GLOBAL HOSPITALS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 36 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 37 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 38 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 39 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 40 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 41 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 42 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 43 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 44 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 45 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 46 US CANCER STATISTICS (2020)
TABLE 47 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 48 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 49 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 50 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 51 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 52 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 53 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 54 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 55 GERMANY CANCER STATISTICS (2020)
TABLE 56 FRANCE CANCER STATISTICS (2020)
TABLE 57 UK CANCER STATISTICS (2020)
TABLE 58 ITALY CANCER STATISTICS (2020)
TABLE 59 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 60 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 61 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 62 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 63 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 64 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 65 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 66 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 67 CHINA CANCER STATISTICS (2020)
TABLE 68 JAPAN CANCER STATISTICS (2020)
TABLE 69 INDIA CANCER STATISTICS (2020)
TABLE 70 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 71 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 72 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 73 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 74 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 75 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 76 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 77 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 78 BRAZIL CANCER STATISTICS (2020)
TABLE 79 MEXICO CANCER STATISTICS (2020)
TABLE 80 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 81 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 82 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 83 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 84 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 85 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 86 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 87 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 88 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 89 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 90 DANAHER: MAJOR PRODUCT OFFERINGS
TABLE 91 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 92 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 93 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS
TABLE 94 BD: MAJOR PRODUCT OFFERINGS
TABLE 95 BILLIONTOONE: MAJOR PRODUCT OFFERINGS
TABLE 96 BIOCARTIS: MAJOR PRODUCT OFFERINGS
TABLE 97 BIODESIX: MAJOR PRODUCT OFFERINGS
TABLE 98 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS
TABLE 99 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 100 CARIS LIFE SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 101 EPIGENOMICS: MAJOR PRODUCT OFFERINGS
TABLE 102 EXACT SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 103 GUARDANT HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 104 HOLOGIC: MAJOR PRODUCT OFFERINGS
TABLE 105 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 106 LABORATORY CORPORATION OF AMERICA: MAJOR PRODUCT OFFERINGS
TABLE 107 LEPU MEDICAL TECHNOLOGY (BEIJING): MAJOR PRODUCT OFFERINGS
TABLE 108 MYRIAD GENETICS: MAJOR PRODUCT OFFERINGS
TABLE 109 SYSMEX CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 110 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 111 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 112 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 113 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 114 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 115 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 116 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 117 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 118 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 119 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 120 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 121 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 ($ MILLION)
TABLE 122 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY PRODUCT TYPE 2022−2028 (%)
TABLE 123 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 124 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 125 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 126 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 127 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 128 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 129 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 130 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 131 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 132 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 133 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 ($ MILLION)
TABLE 134 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY CANCER TYPE 2022−2028 (%)
TABLE 135 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 136 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 137 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 138 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 139 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 140 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 141 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 142 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 143 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 144 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 145 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ MILLION)
TABLE 146 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 147 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 148 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 149 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 150 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 151 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 152 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 153 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 154 APAC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 155 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 156 LATIN AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 157 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ MILLION)
TABLE 158 MIDDLE EAST & AFRICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 159 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 160 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 161 GLOBAL KITS & REAGENTS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 162 GLOBAL KITS & REAGENTS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 163 GLOBAL INSTRUMENTS & PLATFORM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 164 GLOBAL INSTRUMENTS & PLATFORM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 165 GLOBAL BREAST CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 166 GLOBAL BREAST CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 167 COLORECTAL CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 168 GLOBAL COLORECTAL CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 169 GLOBAL LUNG CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 170 GLOBAL LUNG CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 171 GLOBAL BLOOD CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 172 GLOBAL BLOOD CANCER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 173 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 174 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 175 GLOBAL PCR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 176 GLOBAL PCR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 177 GLOBAL HYBRIDIZATION ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 178 GLOBAL HYBRIDIZATION ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 179 GLOBAL INAAT ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 180 GLOBAL INAAT ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 181 GLOBAL SEQUENCING ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 182 GLOBAL SEQUENCING ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 183 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 184 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 185 GLOBAL DIAGNOSTIC LABORATORIES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 186 GLOBAL DIAGNOSTIC LABORATORIES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 187 GLOBAL HOSPITALS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 188 GLOBAL HOSPITALS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 189 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ MILLION)
TABLE 190 GLOBAL OTHER ONCOLOGY MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT TYPE
4.3.2 MARKET SEGMENTATION BY CANCER TYPE
4.3.3 MARKET SEGMENTATION BY TECHNOLOGY
4.3.4 MARKET SEGMENTATION BY END-USER
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 PREMIUM INSIGHTS
6.1 OVERVIEW
6.1.1 GEOGRAPHY INSIGHTS
6.1.2 PRODUCT TYPE INSIGHTS
6.1.3 CANCER TYPE INSIGHTS
6.1.4 TECHNOLOGY INSIGHTS
6.1.5 END-USER INSIGHTS
7 MARKET AT A GLANCE
8 INTRODUCTION
8.1 OVERVIEW
8.1.1 MOLECULAR DIAGNOSTICS IN ONCOLOGY
9 MARKET OPPORTUNITIES & TRENDS
9.1 GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS FOR ONCOLOGY DRUG DEVELOPMENT
9.2 INCREASING PARTNERSHIPS & COLLABORATION FOR DEVELOPMENT OF ONCOLOGY MOLECULAR DIAGNOSTICS
9.3 EMERGING IMMUNO-ONCOLOGY-BASED CANCER TREATMENTS
10 MARKET GROWTH ENABLERS
10.1 RISING GLOBAL CANCER PREVALENCE
10.2 TRANSFORMATION OF PRECISION CANCER CARE
10.3 NEW PRODUCT LAUNCHES
10.4 TECHNOLOGICAL ADVANCES IN MOLECULAR DIAGNOSTICS
11 MARKET RESTRAINTS
11.1 HIGH COST OF MOLECULAR DIAGNOSTICS TESTS
11.2 LACK OF SKILLED WORKFORCE & OPERATIONAL BARRIERS
11.3 AVAILABILITY OF ALTERNATIVE TECHNOLOGIES IN CANCER DIAGNOSIS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET BY GEOGRAPHY
12.3.2 MARKET BY PRODUCT TYPE
12.3.3 MARKET BY CANCER TYPE
12.3.4 MARKET BY TECHNOLOGY
12.3.5 MARKET BY END-USER
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 PRODUCT TYPE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 KITS & REAGENTS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 KITS & REAGENTS BY GEOGRAPHY
13.4 INSTRUMENTS & PLATFORMS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 INSTRUMENTS & PLATFORM BY GEOGRAPHY
14 CANCER TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 BREAST CANCER
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 BREAST CANCER BY GEOGRAPHY
14.4 COLORECTAL CANCER
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 COLORECTAL CANCER BY GEOGRAPHY
14.5 LUNG CANCER
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 LUNG CANCER BY GEOGRAPHY
14.6 BLOOD CANCER
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 BLOOD CANCER BY GEOGRAPHY
14.7 OTHERS
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 OTHER BY GEOGRAPHY
15 TECHNOLOGY
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 POLYMERASE CHAIN REACTION (PCR)
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 PCR BY GEOGRAPHY
15.4 HYBRIDIZATION
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 HYBRIDIZATION BY GEOGRAPHY
15.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 INAAT BY GEOGRAPHY
15.6 SEQUENCING
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST
15.6.3 SEQUENCING BY GEOGRAPHY
15.7 OTHER
15.7.1 MARKET OVERVIEW
15.7.2 MARKET SIZE & FORECAST
15.7.3 OTHER BY GEOGRAPHY
16 END-USER
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 DIAGNOSTIC LABORATORIES
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 DIAGNOSTIC LABORATORIES BY GEOGRAPHY
16.4 HOSPITALS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 HOSPITALS BY GEOGRAPHY
16.5 OTHER
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 OTHER BY GEOGRAPHY
17 GEOGRAPHY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 GEOGRAPHIC OVERVIEW
18 NORTH AMERICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 NORTH AMERICA MARKET BY PRODUCT TYPE
18.2.2 NORTH AMERICA MARKET BY CANCER TYPE
18.2.3 NORTH AMERICA MARKET BY TECHNOLOGY
18.2.4 NORTH AMERICA MARKET BY END-USER
18.3 KEY COUNTRIES
18.3.1 US: MARKET SIZE & FORECAST
18.3.2 CANADA: MARKET SIZE & FORECAST
19 EUROPE
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 EUROPE MARKET BY PRODUCT TYPE
19.2.2 EUROPE MARKET BY CANCER TYPE
19.2.3 EUROPE MARKET BY TECHNOLOGY
19.2.4 EUROPE MARKET BY END-USER
19.3 KEY COUNTRIES
19.3.1 GERMANY: MARKET SIZE & FORECAST
19.3.2 FRANCE: MARKET SIZE & FORECAST
19.3.3 UK: MARKET SIZE & FORECAST
19.3.4 ITALY: MARKET SIZE & FORECAST
19.3.5 SPAIN: MARKET SIZE & FORECAST
20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 APAC MARKET BY PRODUCT TYPE
20.2.2 APAC MARKET BY CANCER TYPE
20.2.3 APAC MARKET BY TECHNOLOGY
20.2.4 APAC MARKET BY END-USER
20.3 KEY COUNTRIES
20.3.1 CHINA: MARKET SIZE & FORECAST
20.3.2 JAPAN: MARKET SIZE & FORECAST
20.3.3 INDIA: MARKET SIZE & FORECAST
20.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
20.3.5 AUSTRALIA: MARKET SIZE & FORECAST
21 LATIN AMERICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 LATIN AMERICA MARKET BY PRODUCT TYPE
21.2.2 LATIN AMERICA MARKET BY CANCER TYPE
21.2.3 LATIN AMERICA MARKET BY TECHNOLOGY
21.2.4 LATIN AMERICA MARKET BY END-USER
21.3 KEY COUNTRIES
21.3.1 BRAZIL: MARKET SIZE & FORECAST
21.3.2 MEXICO: MARKET SIZE & FORECAST
21.3.3 ARGENTINA: MARKET SIZE & FORECAST
22 MIDDLE EAST & AFRICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
22.2.2 MIDDLE EAST & AFRICA MARKET BY CANCER TYPE
22.2.3 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
22.2.4 MIDDLE EAST & AFRICA MARKET BY END-USER
22.3 KEY COUNTRIES
22.3.1 TURKEY: MARKET SIZE & FORECAST
22.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
22.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST
23 COMPETITIVE LANDSCAPE
23.1 COMPETITION OVERVIEW
23.2 MARKET SHARE ANALYSIS
23.2.1 ABBOTT
23.2.2 AGILENT TECHNOLOGIES
23.2.3 DANAHER
23.2.4 F. HOFFMANN LA-ROCHE
23.2.5 QIAGEN
23.2.6 SIEMENS HEALTHINEERS
24 KEY COMPANY PROFILES
24.1 ABBOTT
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.1.3 KEY STRATEGIES
24.1.4 KEY STRENGTHS
24.1.5 KEY OPPORTUNITIES
24.2 AGILENT TECHNOLOGIES
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.2.3 KEY STRATEGIES
24.2.4 KEY STRENGTHS
24.2.5 KEY OPPORTUNITIES
24.3 DANAHER
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.3.3 KEY STRATEGIES
24.3.4 KEY STRENGTHS
24.3.5 KEY OPPORTUNITIES
24.4 F. HOFFMANN-LA ROCHE
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.4.3 KEY STRATEGIES
24.4.4 KEY STRENGTHS
24.4.5 KEY OPPORTUNITIES
24.5 QIAGEN
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.5.3 KEY STRATEGIES
24.5.4 KEY STRENGTHS
24.5.5 KEY OPPORTUNITIES
24.6 SIEMENS HEALTHINEERS
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.6.3 KEY STRATEGIES
24.6.4 KEY STRENGTHS
24.6.5 KEY OPPORTUNITIES
25 OTHER PROMINENT VENDORS
25.1 BD
25.1.1 BUSINESS OVERVIEW
25.1.2 PRODUCT OFFERINGS
25.2 BILLIONTOONE
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT OFFERINGS
25.3 BIOCARTIS
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT OFFERINGS
25.4 BIODESIX
25.4.1 BUSINESS OVERVIEW
25.4.2 PRODUCT OFFERINGS
25.5 BIOMÉRIEUX
25.5.1 BUSINESS OVERVIEW
25.5.2 PRODUCT OFFERINGS
25.6 BIO-RAD LABORATORIES
25.6.1 BUSINESS OVERVIEW
25.6.2 PRODUCT OFFERINGS
25.7 CARIS LIFE SCIENCES
25.7.1 BUSINESS OVERVIEW
25.7.2 PRODUCT OFFERINGS
25.8 EPIGENOMICS
25.8.1 BUSINESS OVERVIEW
25.8.2 PRODUCT OFFERINGS
25.9 EXACT SCIENCES
25.9.1 BUSINESS OVERVIEW
25.9.2 PRODUCT OFFERINGS
25.10 GUARDANT HEALTH
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT OFFERINGS
25.11 HOLOGIC
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT OFFERINGS
25.12 ILLUMINA
25.12.1 BUSINESS OVERVIEW
25.12.2 PRODUCT OFFERINGS
25.13 LABORATORY CORPORATION OF AMERICA
25.13.1 BUSINESS OVERVIEW
25.13.2 PRODUCT OFFERINGS
25.14 LEPU MEDICAL TECHNOLOGY (BEIJING)
25.14.1 BUSINESS OVERVIEW
25.14.2 PRODUCT OFFERINGS
25.15 MYRIAD GENETICS
25.15.1 BUSINESS OVERVIEW
25.15.2 PRODUCT OFFERINGS
25.16 SYSMEX CORPORATION
25.16.1 BUSINESS OVERVIEW
25.16.2 PRODUCT OFFERINGS
25.17 THERMO FISHER SCIENTIFIC
25.17.1 BUSINESS OVERVIEW
25.17.2 PRODUCT OFFERINGS
26 REPORT SUMMARY
26.1 KEY TAKEAWAYS
26.2 STRATEGIC RECOMMENDATIONS
27 QUANTITATIVE SUMMARY
27.1 MARKET BY PRODUCT TYPE
27.1.1 NORTH AMERICA MARKET BY PRODUCT TYPE
27.1.2 EUROPE MARKET BY PRODUCT TYPE
27.1.3 APAC MARKET BY PRODUCT TYPE
27.1.4 LATIN AMERICA MARKET BY PRODUCT TYPE
27.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
27.2 MARKET BY CANCER TYPE
27.2.1 NORTH AMERICA MARKET BY CANCER TYPE
27.2.2 EUROPE MARKET BY CANCER TYPE
27.2.3 APAC MARKET BY CANCER TYPE
27.2.4 LATIN AMERICA MARKET BY CANCER TYPE
27.2.5 MIDDLE EAST & AFRICA MARKET BY CANCER TYPE
27.3 MARKET BY TECHNOLOGY
27.3.1 NORTH AMERICA MARKET BY TECHNOLOGY
27.3.2 EUROPE MARKET BY TECHNOLOGY
27.3.3 APAC MARKET BY TECHNOLOGY
27.3.4 LATIN AMERICA MARKET BY TECHNOLOGY
27.3.5 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
27.4 MARKET BY END-USER
27.4.1 NORTH AMERICA MARKET BY END-USER
27.4.2 EUROPE MARKET BY END-USER
27.4.3 APAC MARKET BY END-USER
27.4.4 LATIN AMERICA MARKET BY END-USER
27.4.5 MIDDLE EAST & AFRICA MARKET BY END-USER
27.5 MARKET BY GEOGRAPHY
27.5.1 KITS & REAGENTS BY GEOGRAPHY
27.5.2 INSTRUMENTS & PLATFORM BY GEOGRAPHY
27.5.3 BREAST CANCER BY GEOGRAPHY
27.5.4 COLORECTAL CANCER BY GEOGRAPHY
27.5.5 LUNG CANCER BY GEOGRAPHY
27.5.6 BLOOD CANCER BY GEOGRAPHY
27.5.7 OTHER BY GEOGRAPHY
27.5.8 PCR BY GEOGRAPHY
27.5.9 HYBRIDIZATION BY GEOGRAPHY
27.5.10 INAAT BY GEOGRAPHY
27.5.11 SEQUENCING BY GEOGRAPHY
27.5.12 OTHER BY GEOGRAPHY
27.5.13 DIAGNOSTIC LABORATORIES BY GEOGRAPHY
27.5.14 HOSPITALS BY GEOGRAPHY
27.5.15 OTHER BY GEOGRAPHY
28 APPENDIX
28.1 ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the oncology molecular diagnostics market?
What is the growth rate of the global oncology molecular diagnostics market?
Which region dominates the global oncology molecular diagnostics market share?
What are the significant trends in the oncology molecular diagnostics market?
Who are the key players in the global oncology molecular diagnostics market?
other RELATED Reports
In Vitro Diagnostics Market - Global Outlook & Forecast 2023-2028
Published : February 2023
